ArticlePatient preference and adherence2025
Validation of Basque "Test of Adherence to Inhalers" in Asthma and Chronic Obstructive Pulmonary Disease.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing towards personalized medicine: Practical specifications for management of treatable traits in patients with COPD exacerbations.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To adapt the Test of Adherence to Inhalers (TAI) questionnaire to Basque language and evaluate the psychometric properties. Patients and Methods: A cross-sectional observational study was carried out. We recruited Basque-speaking adults aged ≥18 years who attended the respiratory outpatient clinics in the last 5 years for follow-up with a diagnosis of asthma (n=249) or chronic obstructive pulmonary disease (COPD) (n=149). Patients were contacted by postal mail and reminders were sent to non-respondents. The TAI was translated into Basque and back-translated into Spanish. The comprehensibility and feasibility of Basque TAI were evaluated through cognitive debriefing interviews. We performed the descriptive of the questionnaire and assessed reliability by Cronbach's alpha, structure validity by confirmatory factor analysis (CFA) and known-groups validity by Wilcoxon and Kruskal-Wallis tests according to disease severity, exacerbations and Charlson Comorbidity Index (CCI). Results: Mean TAI score were 44.82 (standard deviation (SD)=7.26) and 48.52 (SD=3.88) for patients with asthma and COPD, respectively. No floor effect was observed in any cohort. 38.14% of patients with asthma and 67.21% with COPD reported good adherence (maximum score), indicating a ceiling effect. The Cronbach's alphas were 0.881 and 0.836 for the asthma and COPD cohorts, respectively, demonstrating adequate reliability. In the CFA, each item loading was >0.4, suggesting that they fit into a single dimension. Mean TAI score was higher in patients with asthma experiencing exacerbations (p<0.05) and more severe asthma and COPD (p<0.0001) as compared to their counterparts, which demonstrates the known-groups validity. TAI score did not differ according to comorbidities. Conclusion: The Basque TAI is valid, reliable and useful for measuring adherence to inhalers in patients with asthma and COPD in clinical and research settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.